

Erin Grace Sparrow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9054077/publications.pdf>

Version: 2024-02-01

13
papers

426
citations

1162367

8
h-index

1199166

12
g-index

13
all docs

13
docs citations

13
times ranked

865
citing authors

#	ARTICLE	IF	CITATIONS
1	WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use. <i>Vaccine</i> , 2022, 40, 3506-3510.	1.7	20
2	Technology transfer programme for influenza vaccines – Lessons from the past to inform the future. <i>Vaccine</i> , 2022, , .	1.7	0
3	Global production capacity of seasonal and pandemic influenza vaccines in 2019. <i>Vaccine</i> , 2021, 39, 512-520.	1.7	63
4	A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults. <i>Vaccines</i> , 2020, 8, 296.	2.1	4
5	Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. <i>Vaccine</i> , 2019, 37, A132-A139.	1.7	43
6	Two Live Attenuated Vaccines against Recent Low- and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets. <i>Vaccines</i> , 2018, 6, 74.	2.1	6
7	Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. <i>PLoS ONE</i> , 2018, 13, e0208028.	1.1	18
8	Cross-Protective Efficacy of Monovalent Live Influenza B Vaccines against Genetically Different Lineages of B/Victoria and B/Yamagata in Ferrets. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	6
9	Therapeutic antibodies for infectious diseases. <i>Bulletin of the World Health Organization</i> , 2017, 95, 235-237.	1.5	96
10	Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. <i>Vaccine</i> , 2016, 34, 5442-5448.	1.7	63
11	Stakeholders'™ perceptions of 10 years of the Global Action Plan for Influenza Vaccines (GAP) – Results from a survey. <i>Vaccine</i> , 2016, 34, 5393-5399.	1.7	3
12	The 2015 global production capacity of seasonal and pandemic influenza vaccine. <i>Vaccine</i> , 2016, 34, 5410-5413.	1.7	69
13	H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 303-310.	4.6	35